The Evaluation of Ischemia Modified Albumin and Adropin Levels in Patients with Pulmonary Embolism

Abstract

Pulmonary embolism (PE) is a serious clinical condition and difficult to be diagnosed. The aim of the present study was to evaluate plasma adropin and ischemia-modified albumin (IMA) levels in the patients with PE. Methods:The study consisted of 109 participants, including 50 patients with PE and 59 healthy individuals. The patients diagnosed with PE through computed tomography pulmonary angiography (CTPA) were included into the study. Plasma adropin and IMA concentrations were measured by an enzyme-linked immunosorbent assay kit. Results:The patients with PE had higher plasma adropin (607.5±205.1 ng/mL) and lower IMA (2128.6±801.8 ng/mL) levels, compared with those in the controls (505.5±231.3 ng/mL and 2466.9±1044.9 ng/mL, respectively); however, the difference was not significant. In the study, we found a weak and negative correlation between adropin and IMA levels in the patients with PE (p=0.020, r=-0.348). Conclusions:In our study among the patients with PE, there was no significant difference between adropin and IMA levels, although plasma atropin concentrations were high, and IMA concentrations were low. So, we consider that both IMA and adropin are inappropriate markers for the diagnosis of PE.